Search and analyze individual stocks with comprehensive metrics

InMed Pharmaceuticals Inc

INMFurniture, Home Furnishing
223.00+0.00 (+0.00%)
As on 15 Jan 2026, 05:48 amMarket Open

Fundamental Score

...

InMed Pharmaceuticals Inc Share Price Live NSE/BSE

No data
High
0.00
Low
0.00
Volume
0
Change
+0.00%

Profitability Metrics

Excellent

Return on Equity

19.56%
Excellent

Return on Capital Employed

21.67%

Operating Profit Margin (5Y)

N/A
Poor

Dividend Yield

0.09%

Valuation Metrics

Good

Price to Earnings

35.59x

Market Capitalization

388.24 (Cr)

Industry P/E

39.98x

Growth Metrics

Poor

YoY Quarterly Profit Growth

-25.48%
Excellent

YoY Quarterly Sales Growth

24.29%

Sales Growth (5Y)

N/A

EPS Growth (5Y)

N/A

Profit Growth (5Y)

N/A

Financial Health

Poor

Debt to Equity

0.71x
Excellent

Interest Coverage

10.41x

Free Cash Flow (5Y)

N/A

Ownership Structure

Good

Promoter Holding

68.54%
Average

FII Holding

5.26%
Poor

DII Holding

0.00%
Good

Pledged Percentage

0.63%
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.
68.54%
Promoter Holding
388.24 (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of INM across key market metrics for learning purposes.

Positive Indicators

5 factors identified

Strong Return on Equity (19.56%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (21.67%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.

Strong Revenue Growth (24.29%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.

Strong Interest Coverage (10.41x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.

Balanced Promoter Holding (68.54%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.

Risk Factors

4 factors identified

Profit Decline Concern (-25.48%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.

Limited Institutional Interest (FII+DII: 5.26%)

Observation: Low institutional participation may affect liquidity and visibility.

Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.

High P/E Ratio

Observation: Stock may be overvalued relative to earnings.

Analysis: P/E above 30 requires strong growth execution to justify current valuations.

Small Market Cap

Observation: Higher investment risk due to limited size.

Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.

Loading Peer Comparison

Finding companies in the Furniture, Home Furnishing sector...

Financial Statements

Comprehensive financial data for InMed Pharmaceuticals Inc

INM Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)19.56%
Return on Capital Employed21.67%
Operating Profit Margin (5Y)N/A%
Debt to Equity Ratio0.71
Interest Coverage Ratio10.41

Growth & Valuation

Sales Growth (5Y)N/A%
Profit Growth (5Y)N/A%
EPS Growth (5Y)N/A%
YoY Quarterly Profit Growth-25.48%
YoY Quarterly Sales Growth24.29%

Frequently Asked Questions

What is the current price of InMed Pharmaceuticals Inc (INM)?

As of 15 Jan 2026, 05:48 am IST, InMed Pharmaceuticals Inc (INM) is currently trading at ₹223.00. The stock has a market capitalization of ₹388.24 (Cr).

Is INM share price Overvalued or Undervalued?

INM is currently trading at a P/E ratio of 35.59x, compared to the industry average of 39.98x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.

What factors affect the InMed Pharmaceuticals Inc share price?

Key factors influencing INM's price include its quarterly earnings growth (Sales Growth: 24.29%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is InMed Pharmaceuticals Inc a good stock for long-term investment?

InMed Pharmaceuticals Inc shows a 5-year Profit Growth of N/A% and an ROE of 19.56%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.71 before investing.

How does InMed Pharmaceuticals Inc compare with its industry peers?

InMed Pharmaceuticals Inc competes with major peers in the Furniture, Home Furnishing. Investors should compare INM's P/E of 35.59x and ROE of 19.56% against the industry averages to determine its competitive standing.

What is the P/E ratio of INM and what does it mean?

INM has a P/E ratio of 35.59x compared to the industry average of 39.98x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹36 for every ₹1 of annual earnings.

How is INM performing according to Bull Run's analysis?

INM has a Bull Run fundamental score of 32.1/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.

What sector and industry does INM belong to?

INM operates in the Furniture, Home Furnishing industry. This classification helps understand the competitive landscape and sector-specific trends affecting InMed Pharmaceuticals Inc.

What is Return on Equity (ROE) and why is it important for INM?

INM has an ROE of 19.56%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently InMed Pharmaceuticals Inc generates profits from shareholders' equity.

How is INM's debt-to-equity ratio and what does it indicate?

INM has a debt-to-equity ratio of 0.71, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.

What is INM's dividend yield and is it a good dividend stock?

INM offers a dividend yield of 0.09%, which means you receive ₹0.09 annual dividend for every ₹100 invested.

How has INM grown over the past 5 years?

INM has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.

What is the promoter holding in INM and why does it matter?

Promoters hold 68.54% of INM shares, with 0.63% of promoter shares pledged. High promoter holding often indicates strong management confidence.

What is INM's market capitalization category?

INM has a market capitalization of ₹388 crores, placing it in the Small-cap category.

How volatile is INM stock?

INM has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is the 52-week high and low for INM?

INM has a 52-week high of ₹N/A and low of ₹N/A.

What is INM's operating profit margin trend?

INM has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.

How is INM's quarterly performance?

Recent quarterly performance shows YoY Sales Growth of 24.29% and YoY Profit Growth of -25.48%.

What is the institutional holding pattern in INM?

INM has FII holding of 5.26% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.